
Merck KGaA buys medtech assets for $11.3B, reshaping Europe’s healthcare M&A chessboard
The German pharma-to-medtech swing signals a big bet on growth plus tougher competition for deal makers and regulators.
By Hessa Al-Faleh·· 3 min
1 briefing · “medtech”

The German pharma-to-medtech swing signals a big bet on growth plus tougher competition for deal makers and regulators.